secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2021-12-09T23:59:59+00:00
Accession:  0001193125-21-352727
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio appoints Kate Rochlin as Chief Operating Officer effective Dec 1, 2021
-----------------------------------------------------------------------------

- Kate Rochlin, Ph.D. appointed COO; will receive $400,000 base salary and 40% bonus eligibility.
- Rochlin previously served as VP, Operations and Innovation at IN8bio since December 2020.
- She holds a Ph.D. in Cell and Developmental Biology from Weill Cornell and a B.A. from University of Pennsylvania.
- No related-party transactions disclosed with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312521352727/0001193125-21-352727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312521352727/d250286d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-352727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer